Zortress Oral Tablet 0.25Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Zortress: Oral tablet (0.25mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

EVEROLIMUS (eve ROE li mus) decreases the activity of your immune system. Afinitor is used to treat certain types of cancer. Zortress is used for kidney and liver transplant rejection prophylaxis.

In-Depth Information

Zortress 0.25mg Tablet

NDC: 000780417
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Breast Cancer, Liver Transplant Rejection Prophylaxis, Kidney Transplant Rejection Prophylaxis, Carcinoid, Renal Cell Cancer, Neuroendocrine Tumor (NET), Astrocytoma, Renal Angiomyolipoma

Storage Information
Protect from light
Protect from moisture
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Zortress 0.25mg Tablet

Reported Side Effects for Zortress 0.25mg Tablet

Fluid Retention Incidence:
<3.0%*
Severity: SEVERE
Onset: DELAYED
Inflamed Pancreas Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Low White Blood Cell Counts Incidence:
<2.0%*
Severity: SEVERE
Onset: DELAYED
Moschcowitz Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Inflamed Blood Vessels Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Increased Blood Sugar Incidence:
<17.0%*
Severity: SEVERE
Onset: DELAYED
Hemolytic-uremic Syndrome Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Lung Inflammation Incidence:
<4.2%*
Severity: SEVERE
Onset: DELAYED
Fluid Around The Heart Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Decreased Healing Incidence:
<10.0%*
Severity: MODERATE
Onset: DELAYED
Exfoliative Dermatitis Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Angioedema Incidence:
<6.8%*
Severity: SEVERE
Onset: RAPID
Blood Clot Incidence:
<10.0%*
Severity: SEVERE
Onset: DELAYED
Nose Bleed Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Fever Incidence:
0.2-6.0%*
Severity: SEVERE
Onset: EARLY
Itching Incidence:
0.2-1.0%*
Severity: SEVERE
Onset: RAPID
Inability To Sleep Incidence:
0.2%*
Severity: SEVERE
Onset: EARLY
Back Pain Incidence:
0.2-1.0%*
Severity: SEVERE
Onset: DELAYED
Headache Incidence:
0.4-1.0%*
Severity: SEVERE
Onset: EARLY
Lightheadedness Incidence:
0.5%*
Severity: SEVERE
Onset: EARLY
Cough Incidence:
0.6%*
Severity: SEVERE
Onset: DELAYED
High Cholesterol Incidence:
0.8-1.0%*
Severity: SEVERE
Onset: DELAYED
Joint Pain Incidence:
0.8-1.5%*
Severity: SEVERE
Onset: DELAYED
High Triglycerides Incidence:
0.8-4.0%*
Severity: SEVERE
Onset: DELAYED
Chills Incidence:
1.0-10.0%*
Severity: MILD
Onset: RAPID
Chest Pain Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: EARLY
Blurred Vision Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: EARLY
Drug-Induced Acne Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Lack Of Vitamin B12 Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Weakness Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Wound Dehiscence Incidence:
1.0-10.0%*
Severity: SEVERE
Onset: DELAYED
Wheezing Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: RAPID
Rapid Heart Rate Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: EARLY
Dead Bone Incidence:
1.0-10.0%*
Severity: SEVERE
Onset: DELAYED
Night Sweats Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Osteopenia Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Muscle And/Or Bone Pain Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Cyst Of Lymph Fluid Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Enlarged Lymph Nodes Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Paresis Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Paresthesias Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Hypoesthesia Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Ambras Syndrome Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
High Blood Pressure Incidence:
1.0-10.0%*
Severity: SEVERE
Onset: EARLY
Bruise Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: EARLY
Hallucinations Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: EARLY
Skin Rash Incidence:
1.0%*
Severity: SEVERE
Onset: EARLY
Fluid Retention Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Kidney Damage Incidence:
1.0-10.0%*
Severity: SEVERE
Onset: DELAYED
Cushingoid Features Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Conjunctivitis Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Rapid Heart Rate Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: RAPID
Distressed Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Hair Loss Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Chest Pain Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: EARLY
Nervousness Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Extra Abdominal Fluid Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Irregular Heart Beat Incidence:
1.0-10.0%*
Severity: SEVERE
Onset: EARLY
Depression Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Drowsiness Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Gout Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Heart Failure Incidence:
1.0-10.0%*
Severity: SEVERE
Onset: DELAYED
Hirsutism Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Excessive Sweating Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
High Blood Pressure Incidence:
1.0%*
Severity: SEVERE
Onset: EARLY
High Uric Acid Level Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Low Calcium Levels Incidence:
1.0-37.0%*
Severity: MODERATE
Onset: DELAYED
Low Blood Sodium Levels Incidence:
1.0%*
Severity: SEVERE
Onset: DELAYED
Fainting Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
High White Blood Cells Incidence:
1.0-10.0%*
Severity: MILD
Onset: DELAYED
Cataracts Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
High Platelet Count Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Low Platelet Count Incidence:
1.0-3.0%*
Severity: SEVERE
Onset: DELAYED
Runny Nose Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Fluid In Lungs Incidence:
1.0-10.0%*
Severity: SEVERE
Onset: EARLY
Protein In The Urine Incidence:
1.0-18.0%*
Severity: MODERATE
Onset: DELAYED
Low Phosphate Level Incidence:
1.0-10.0%*
Severity: SEVERE
Onset: DELAYED
Low Blood Pressure Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: RAPID
Muscle Pain Incidence:
1.0-11.0%*
Severity: MILD
Onset: EARLY
Stuffy Nose Incidence:
1.0-10.0%*
Severity: MILD
Onset: EARLY
Osteoporosis Incidence:
1.0-10.0%*
Severity: MODERATE
Onset: DELAYED
Fluid Around The Lungs Incidence:
1.0-10.0%*
Severity: SEVERE
Onset: DELAYED
Swelling Incidence:
1.5%*
Severity: SEVERE
Onset: DELAYED
Diabetes Incidence:
2.0%*
Severity: SEVERE
Onset: DELAYED
Low Potassium Levels Incidence:
2.0-4.2%*
Severity: SEVERE
Onset: DELAYED
Shortness Of Breath Incidence:
2.5-7.0%*
Severity: SEVERE
Onset: EARLY
Dehydration Incidence:
>3.0%*
Severity: SEVERE
Onset: DELAYED
Tired Incidence:
3.5-5.0%*
Severity: SEVERE
Onset: EARLY
Feeling Sick Incidence:
3.5%*
Severity: SEVERE
Onset: EARLY
Mouth Sores Incidence:
4.0-9.0%*
Severity: SEVERE
Onset: DELAYED
Mouth Ulcers Incidence:
4.0-9.0%*
Severity: SEVERE
Onset: DELAYED
High Potassium Level Incidence:
7.0-18.0%*
Severity: SEVERE
Onset: DELAYED
Shaking Incidence:
8.0%*
Severity: MILD
Onset: EARLY
Low Magnesium Levels Incidence:
14.0%*
Severity: MODERATE
Onset: DELAYED
Increased Blood Fats Incidence:
21.0%*
Severity: MODERATE
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Daily Life Interactions for Zortress 0.25mg Tablet

Elements of your daily lifestyle may have an effect on the medications you are taking. Drug interactions can result in unwanted side effects, reduce the effectiveness of your medicine or possibly increase the action of a particular medicine.

Major Lifestyle Interaction
Grapefruit juice and Zortress 0.25mg Tablet(Everolimus)
Grapefruit juice and Everolimus(Everolimus)
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Avoid - This drug is known to cause harm to infants when taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Zortress

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.